UK Markets open in 6 hrs 18 mins

Middle East Respiratory Syndrome (MERS) Pipeline Landscape 2020

Research and Markets
·5-min read

Dublin, Sept. 30, 2020 (GLOBE NEWSWIRE) -- The "Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Middle East Respiratory Syndrome - Pipeline Review, H1 2020, provides an overview of the Middle East Respiratory Syndrome (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Middle East Respiratory Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 17, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 7 molecules, respectively.

Middle East Respiratory Syndrome (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Middle East Respiratory Syndrome (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  1. Introduction

  2. Middle East Respiratory Syndrome (MERS) - Overview

  3. Middle East Respiratory Syndrome (MERS) - Therapeutics Development

  4. Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment

  5. Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development

  6. Middle East Respiratory Syndrome (MERS) - Drug Profiles

  7. Middle East Respiratory Syndrome (MERS) - Dormant Projects

  8. Middle East Respiratory Syndrome (MERS) - Discontinued Products

  9. Middle East Respiratory Syndrome (MERS) - Product Development Milestones

  10. Appendix

Companies Mentioned

  • AIM ImmunoTech Inc

  • Anglo Biopharma Ltd

  • Atriva Therapeutics GmbH

  • Autoimmune Technologies LLC

  • Celltrion Inc

  • Chongqing Zhifei Biological Products Co Ltd

  • Cocrystal Pharma Inc

  • Future Medicine Co Ltd

  • Gilead Sciences Inc

  • Global BioLife Inc Ltd

  • Greffex Inc

  • Humabs BioMed SA

  • Inovio Pharmaceuticals Inc

  • LegoChem Biosciences Inc

  • NanoViricides Inc

  • Novavax Inc

  • Orgenesis Inc

  • Ostrich Pharma USA Inc

  • OyaGen Inc

  • Phelix Therapeutics LLC

  • Pulmotect Inc

  • Regeneron Pharmaceuticals Inc

  • Ridgeback Biotherapeutics LP

  • Romark Laboratories LC

  • SAB Biotherapeutics Inc

  • Signia Therapeutics

  • AIkido Pharma Inc

  • Sumagen Co Ltd

  • Themis Bioscience GmbH

  • Theravectys SA

  • Vaccitech Ltd

  • VBI Vaccines Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/42c855

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900